Stay updated with breaking news from Alpha portfolio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Глава Приморья посетил дальнереченский детский сад №7 primamedia.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from primamedia.ru Daily Mail and Mail on Sunday newspapers.
«Альфа-Капитал» запускает стратегию «Альфа Портфель Pre-IPO» re-port.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from re-port.ru Daily Mail and Mail on Sunday newspapers.
(0) Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial is being conducted by The University of Texas MD Anderson Cancer Center under an existing strategic research collaboration. Inhibition of the menin protein is being studied as a novel treatment approach for acute leukemias with MLL rearrangement (MLLr) or NPM1 mutation (NPM1m), two gene alterations that drive cancer development and growth. 1 MLLr occurs in approximately 5 to 10% of acute leukemia patients and is associated with aggressive disease, reduced treatment response and poor prognosis. ....
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
(1) Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today that the first patient has been dosed in the first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005385/en/ Despite recent advances in targeted treatment, five-year survival rates for both renal cell carcinoma and ovarian cancer remain low and new therapeutic strategies are needed for tumors that continue to progress on currently available medicines. ....